All In Biotech

NDA 020164 · Sanofi Aventis US

Lovenox (Preservative Free)

Enoxaparin Sodium · Subcutaneous, Intravenous, Subcutaneous

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Mar 29, 1993

Approved uses

9

Original approval plus efficacy supplements

Registered trials

421

139 Phase 3, 34 recruiting

FAERS reports

58,051

50,417 serious, 8,973 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known Monitor patients...

What it is approved for

From the label in effect Sep 17, 2026.

Enoxaparin sodium is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI) ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI) ( 1.4 ) 1.1 Prophylaxis of Deep Vein Thrombosis Enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1) ] in patients undergoing hip replacement surgery, during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness 1.2 Treatment of Acute Deep Vein Thrombosis Enoxaparin sodium is indicated for: the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism , when administered in conjunction with warfarin sodium the outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non–Q-Wave Myocardial Infarction Enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–Q-wave...

Mechanism: Enoxaparin is a low molecular weight heparin which has antithrombotic properties.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 17, 2000 Supplement 36 · Efficacy · priority review LetterLabel
  • Aug 3, 2000 Supplement 20 · Efficacy Letter
  • May 30, 2000 Supplement 34 · Efficacy Letter
  • Dec 31, 1998 Supplement 15 · Efficacy ReviewLetterLabel
  • Mar 27, 1998 Supplement 16 · Efficacy · priority review
  • Jan 30, 1998 Supplement 10 · Efficacy ReviewLetter
  • May 6, 1997 Supplement 8 · Efficacy
  • Mar 9, 1995 Supplement 2 · Efficacy
  • Mar 29, 1993 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDAReviewLetter
9 products under this application
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 40MG/0.4ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX · ENOXAPARIN SODIUM 300MG/3ML (100MG/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AB
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 120MG/0.8ML (150MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 100MG/ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 60MG/0.6ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 30MG/0.3ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 150MG/ML (150MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, SUBCUTANEOUS · Discontinued
  • LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 80MG/0.8ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Enoxaparin" as an intervention, any sponsor and status, largest first.

All 421 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,665
  • dyspnoea2,456
  • nausea2,434
  • diarrhoea2,330
  • anaemia2,259
  • thrombocytopenia2,131
  • pyrexia2,098
  • fatigue2,034
  • vomiting1,905
  • pulmonary embolism1,831
  • death1,772
  • pneumonia1,716

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,257
20051,329
20061,244
20071,240
20081,501
20091,763
20101,941
20112,327
20122,297
20131,935
20142,315
20152,754
20162,904
20172,745
20183,649
20193,436
20203,596
20213,368
20223,956
20233,666
20243,309
20253,268
20262,249

Recalls

1 FDA enforcement reports for this application.

  • Dec 5, 2017 · Class III · Terminated

    Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Oct 20, 2026

    Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...

  • To Be Discontinued · updated Oct 20, 2026

    Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic...

  • To Be Discontinued · updated Oct 20, 2026

    Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...

  • To Be Discontinued · updated Oct 20, 2026

    Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic...

  • To Be Discontinued · updated Oct 20, 2026

    Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...

  • To Be Discontinued · updated Oct 20, 2026

    Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lovenox (Enoxaparin Sodium)

2024 spending

$577K

Beneficiaries

392

950 claims

Per beneficiary

$1,471

$24.80 per unit

View as table
YearSpending
2020$3,499,490
2021$2,848,286
2022$1,795,726
2023$675,990
2024$576,582

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,197 on PubMed

Sponsor: Sanofi · Also marketed as Lovenox

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.